Overview
- Utah’s commerce department launched a first-in-the-country, state‑approved pilot with Doctronic that began in December to handle routine renewals for chronic‑condition patients.
- The effort is described as the first known U.S. program to rely solely on AI for renewals, with eligibility limited to 190 common medications and excluding pain drugs, ADHD treatments and injectables.
- Patients must verify they are in Utah, complete online clinical questions and history checks, and uncertain cases are escalated to physicians who review the first 250 renewals per medication class before autonomy proceeds.
- Physician groups, including the American Medical Association, warn that removing routine physician involvement could miss clinical cues or enable misuse, calling the approach risky.
- Regulatory oversight remains unresolved as the FDA declined to comment, while Doctronic cites malpractice coverage, a temporary $4 per‑renewal fee, internal performance claims, and ongoing expansion talks with other states.